Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 937263-43-9
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Bag,Drum
Delivery Time: 7-15 days
Payment Terms: T/T, L/C, D/A, Western Union
Supply Ability: TON
CAS No:: |
937263-43-9 |
Appearance:: |
Solid Powder |
Molecular Formula:: |
C26H24N8O2 |
Molecular Weight:: |
480.52 |
EINECS:: |
200-001-8 |
MDL NO:: |
MFCD037263439 |
CAS No:: |
937263-43-9 |
Appearance:: |
Solid Powder |
Molecular Formula:: |
C26H24N8O2 |
Molecular Weight:: |
480.52 |
EINECS:: |
200-001-8 |
MDL NO:: |
MFCD037263439 |
Product Description:
Product Name: Irbinitinib CAS 937263-43-9
Synonyms:
N4-(4-([1;4,6-QuinazolinediaMine,N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-;
4,6-Quinazolinediamine,N-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-;
Chemical & Physical Properties
Appearance:Solid powder
Assay: NLT99%
Density:1.41±0.1 g/cm3
Molecular Formula:C26H24N8O2
Molecular Weight:480.52
Storage temp:Store at -20℃
Pka:6.61±0.70
InChIKey:SDEAXTCZPQIFQM-UHFFFAOYSA-N
Uses :
Tukysa (Tucatinib) Tokatinib/Tucatinib (ONT-380) is an oral TKI (Tyrosine kinase) inhibitor with high specificity for HER2. On April 17, 2020, the US FDA approved Tokatinib to be used in combination with Trastuzumab and Capecitabine to treat adult patients with unresectable or metastatic advanced HER2 positive breast cancer.
Tocatinib is a Tyrosine kinase inhibitor of HER2. In vitro, tocatinib inhibits phosphorylation of HER2 and HER3, thereby inhibiting downstream MAPK and AKT signaling and cell proliferation, and exhibits anti-tumor activity in HER2 expressing tumor cells in Chemicalbook. In vivo, the combination of tocatinib and Trastuzumab, which inhibit the growth of HER2 expression by tocatinib, showed increased anti-tumor activity in vitro and in vivo compared with the use of any drug alone.
TUKYSA is a prescription drug that can be used in combination with Trastuzumab and Capecitabine to treat adult breast cancer patients who are positive for human Epidermal growth factor receptor 2 (HER2) and have metastasized (such as brain metastasis) or cannot undergo Mastectomy Chemicalbook. Patients should have received one or more anti HER2 breast cancer drugs. TUKYSA should be used in combination with Trastuzumab and Capecitabine. It is currently unknown whether this drug is safe and effective for children.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.
